Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03306199 · ClinicalTrials.gov registry record
TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
A clinical trial of Peripheral Arterial Disease, sponsored by Spectranetics Corporation.
- Completed
- Registry status
- 82
- Enrollment target
- 1
- Study location
NCT03306199: Completed study of Peripheral Arterial Disease, sponsored by Spectranetics Corporation.
NCT03306199 is a study of Peripheral Arterial Disease that has completed, run by Spectranetics Corporation. The registered enrollment target is 82 participants, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03306199, a study of Peripheral Arterial Disease, has completed, sponsored by Spectranetics Corporation.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).
Primary Outcome
A Target Lesion Revascularization is defined as any percutaneous or surgical intervention to treat a restenosis or reocclusion in the target lesion
Conditions Studied
Interventions
- DEVICE Laser Atherectomy
Study Locations (1)
Louisiana
- Cardiovascular Institute of the South - Houma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2018-06-05 |
What the finished NCT03306199 record still lists
NCT03306199 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Laser Atherectomy is the first listed.
NCT03306199 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT03306199 about?
NCT03306199 is a clinical study titled "TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions". A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).
What is the current status of trial NCT03306199?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2017-10-03. Estimated completion is 2018-06-05.
What conditions does trial NCT03306199 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT03306199?
The interventions under investigation include: Laser Atherectomy (DEVICE).
Who is sponsoring clinical trial NCT03306199?
This trial is sponsored by Spectranetics Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03306199 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03306199's enrollment target sits among peer trials
82 42nd of 79 higher than 38 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI